Low-dose bevacizumab plus atezolizumab enhances transarterial chemoembolization in HCC via correcting vascular-immune niche dysfunction

Journal of Hepatology · Published 2026-07-01 · DOI 10.1016/j.jhep.2026.07.028

Authors (14)

Chenghao Zhao, Huzheng Yan, Zhixing Liang, Haoyuan Yu, Luwen Mu, Zhanwang Xiang, Kun Li, Yongwei Hu, Zhengqi Wu, Tao Pan, Mingming Liu, Yang Yang, Linsen Ye, Mingsheng Huang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Zhao, C., Yan, H., Liang, Z., et al. (2026). Low-dose bevacizumab plus atezolizumab enhances transarterial chemoembolization in HCC via correcting vascular-immune niche dysfunction. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2026.07.028

Related articles